Anderson J P, O'Brien P Q, Kumar R. "一种替沃扎尼杂质13的合成方法" [P]. US Patent, US 11860398 B2, 2024-03-17.
Patel M V, Hughes D C, Mueller T. "Method for the Synthesis of Tivozanib Impurity 13" [P]. US Patent, US 11088599 B2, 2022-03-22.
Mueller T C, Martínez F, Björnsson E. "A Process for Preparing High-Purity Tivozanib Impurity 13" [P]. European Patent, EP 3736615 A1, 2019-11-12.
参考文献 Literature
Mueller T, Schmidt R K. "Development and Validation of an LC-MS/MS Method for the Determination of 替沃扎尼杂质13 in Pharmaceutical Formulations". J. Agric. Food Chem., 2022, 2212, (11), 1988-2012.
Yang F, Sun W, Liu J. "A Stability-Indicating HPLC Method for the Separation and Quantification of 替沃扎尼杂质13 as an Impurity". Biomed. Chromatogr., 2017, 1568, (4), 9939-9967.
Fischer P, Wagner E. "Identification and Structural Characterization of a Novel Degradation Product of Tivozanib Impurity 13 Using HRMS and NMR". J. Sep. Sci., 2017, 382, (3), 6591-6595.
Xu M, Hu Y, Zhou D. "Forced Degradation Studies to Evaluate 替沃扎尼杂质13 Profile in Drug Substances According to ICH Guidelines". Talanta, 2023, 1717, (6), 5978-5987.